News | January 09, 2026
Oculis’ Privosegtor wins FDA breakthrough therapy status for Optic Neuritis
The FDA designation follows visual-function results from the Phase 2 ACUITY trial
The FDA designation follows visual-function results from the Phase 2 ACUITY trial
This is the first controlled pharmacologic study to demonstrate that treatment of obesity improved PsA disease measures
Ventyx's clinical pipeline includes multiple small molecules with potential for oral therapies addressing chronic inflammation
The privately held biotech brings a first-in-class oncology program focused on small molecule–targeted protein degradation
The therapy was well tolerated through Week 24, with a safety profile consistent with Alumis’ Phase 2 data
The trial aims to measure AF burden—the percentage of time patients spend in arrhythmia—as its primary efficacy endpoint
ADHD is a common, chronic neurodevelopmental disorder that often begins in childhood and can persist into adulthood
Sevabertinib is an oral, reversible tyrosine kinase inhibitor (TKI) that directly targets HER2 mutations
The investigational subcutaneous hepcidin mimetic peptide is designed to regulate iron and red blood cell production
Gland Pharma receives approval for Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% (OTC)
Subscribe To Our Newsletter & Stay Updated
